Navigation Links
Protect Pharma Sells Patent Portfolio to Grunenthal GmbH
Date:2/9/2011

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- Protect Pharmaceutical Corporation (OTC Bulletin Board: PRTT) announced today that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market.

Ram Sesha, Protect's Chief Operating Officer, said, "We are very happy to see Protect's programs are innovative and promising enough to attract someone like Grunenthal, a leader in pain drug discovery and research."

Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects. In the near term, Protect intends to proceed with a comprehensive program to develop and commercialize once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy. Protect also plans to develop and commercialize once-daily opioid combinations as well as abuse-deterrent opioid combinations for moderate to severe pain.

About Protect Pharmaceuticals Corporation.

Based in Princeton, New Jersey, Protect (OTC Bulletin Board: PRTT) is a publicly held drug delivery and new product development company. Protect applies its proprietary drug delivery technologies to develop clinically effective drugs and is building a robust pipeline of product candidates based on its proprietary technologies, scientific knowledge and clinical expertise. For more information, visit www.protectpharm.com.

Safe Harbor Statement

This news release may contain certain forward-looking statements and information concerning Protect's business, operations, financial condition and prospects.  These statements are subject to various risks and uncertainties.  Actual results could differ materially from those currently anticipated due to a number of factors.  The information set forth herein should be read in light of such risks and uncertainties.  The Company assumes no duty or obligation to update these statements at any future date.


'/>"/>
SOURCE Protect Pharmaceutical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study
2. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
3. Good Clostridia in the Gut Protect from Allergy and Autoimmunity
4. Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula
5. PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutaneous Coronary Interventions
6. Reportlinker Adds Neuroprotection - Drugs, Markets and Companies
7. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
8. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
9. Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project (QTDP) Grant Under the U.S. Patient Protection and Affordable Care Act of 2010
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016 ... Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation ... Biological Drugs - This New Study Reveals Selling ... Ahead ,What is the future ... the latest technological and commercial analysis. Staying ahead ...
(Date:5/19/2016)... PARIS , May 19,2016 ... Activities at Digestive Disease Week Meeting and 91 ... Society Mauna Kea Technologies (Euronext: MKEA, ... laser endomicroscopy platform, today announced that its Cellvizio ... meeting focused on gastroenterology during the month of ...
(Date:5/19/2016)... , May 19, 2016 BioLight ... an emerging global ophthalmic company focused on the discovery, ... address ophthalmic conditions, announced today that it has obtained ... ) for the manufacturing, distribution, marketing and sales ... treatment of dry eye syndrome (DES) and other ophthalmic ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... ... Edward D. Buckingham, M.D . is excited announce that he has been ... out by the National Consumer Advisory Board to honor excellence in medicine. Only doctors ... award. , The National Consumer Advisory Board (NCAB) is a private organization created to ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical ... representatives from the Japan PMDA, US FDA, industry and academia at the ... help format data from clinical trials so that it can be shared and ...
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, ... host medical device summit on September 15 and 16, 2016 in San Diego, ... former FDA office bearers will be one of the largest gatherings of medical device ...
(Date:5/23/2016)... ... May 23, 2016 , ... In Pursuit of Balance (IPOB) co-founders Jasmine Hirsch ... operations at the end of 2016. , “We created IPOB to change the ... we look back on what we have achieved, we’re gratified by the response of ...
(Date:5/23/2016)... ... 2016 , ... Bio-Optronics, Inc. is delighted to announce recent ... recent and anticipated growth. , Max Elbaz was appointed as Vice President, Sales ... Max joined the Bio-Optronics team in March. His areas of expertise include international ...
Breaking Medicine News(10 mins):